ArticleCommunications biology2025
Vitamin K2 inhibits PGE2-mediated osteoblast ferroptosis by upregulation of CBR1 via the Nrf2/Keap1 pathway.
Article in Communications biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- The gut-bone axis: microbial metabolism and nutritional interventions for bone health.Gut microbes · 2026Review
- The estrogen-ferroptosis axis in postmenopausal osteoporosis, osteoarthritis, and intervertebral disc degeneration: shared mechanisms and emerging evidence.Frontiers in immunology · 2026Review
- Vitamin KDrug design, development and therapy · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Osteoporosis is increasingly attracting attention. Studies have indicated a correlation between vitamin K2 levels and bone mass, but the specific mechanisms remain unclear. Therefore, this study aims to further elucidate the specific molecular mechanisms and related target proteins. We found that serum vitamin K2 level in osteoporosis women was significantly lower than that in normal women. Animal experiments confirmed the anti-osteoporotic effects of vitamin K2. The mechanism and target of vitamin K2 therapy for osteoporosis was investigated through metabolomics and transcriptomics sequencing. Molecular docking was employed to identify downstream target proteins of vitamin K2, while EMSA and ChIP-qPCR were used to explore the specific molecular mechanisms. The results indicate that vitamin K2 promotes bone formation. Additionally, vitamin K2 may bind to the downstream target protein Nrf2 and inhibit Keap1-mediated ubiquitination, and Nrf2 has been shown to up-regulate CBR1 to inhibit osteoblast ferroptosis caused by the inflammatory factor PGE2. In summary, our study demonstrates that Vitamin K2 attenuates bone loss by inhibiting osteoblast ferroptosis, highlighting its therapeutic potential for osteoporosis. These findings advance our understanding of Vitamin K2-mediated osteoprotective effects and facilitate the identification of novel drug targets for osteoporosis treatment.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.